AD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD). Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics, he has overseen.

FORT LAUDERDALE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- AD Mortgage , a leading wholesale lender in the United States, today released findings from its latest broker survey,  Non-QM Fuels Mortgage Industry in 2026  revealing strong momentum for Non-QM lending across the mortgage industry.

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.

VANCOUVER, British Columbia, June 18, 2026 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc., a Vancouver-based biopharmaceutical company focused on skin health and longevity, today announced positive preclinical results for its novel small molecule, DB-006. The compound demonstrated high efficacy in treating atopic dermatitis (AD), significantly reducing key disease drivers, including pruritus (itch), epithelial thickening, inflammation, and immunoglobulin E (IgE) levels.

BRONX, N.Y.--(BUSINESS WIRE)-- #Alzheimers--Oligomerix, Inc., a privately held clinical stage company pioneering the development of oral, small molecule therapeutics targeting Alzheimer's (AD) and rare neurodegenerative diseases, announced an NIH Fast Track Phase II award of $1.9 million from the National Institute on Aging of the National Institutes of Health. This grant supports clinical development of OLX-07010, an orally administered investigational drug, targeting pathological tau aggregates that drive.

CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim results from its ongoing Phase 2 proof-of-concept study of enrupatinib (EI-1071), a brain-penetrant colony-stimulating factor 1 receptor (CSF-1R) inhibitor designed to modulate neuroinflammation in Alzheimer's disease (AD).

Array Digital Infrastructure, Inc. (AD) Shareholder/Analyst Call Prepared Remarks Transcript

PHILADELPHIA, May 15, 2026 /PRNewswire/ -- Stockholder litigation firm Kaskela Law announces that it is investigating Array Digital Infrastructure, Inc. (NYSE: AD) ("Array") on behalf of the company's investors.   Click here for additional information: https://kaskelalaw.com/case/array-digital/ The investigation seeks to determine whether Array and/or the company's officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.

LOS ANGELES, May 14, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of long-term investors in Array Digital Infrastructure, Inc. (“Array Digital” or “the Company”) (NYSE: AD) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Array Digital board breached its fiduciary duties to shareholders, and if the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The firm is investigating whether the company's representatives violated the securities laws or breached their fiduciary duties, causing investor losses Array's stock price has declined over 21% since August 2025 PHILADELPHIA, May 12, 2026 (GLOBE NEWSWIRE) -- Kaskela Law is investigating Array Digital Infrastructure, Inc. (NYSE: AD) (“Array”) on behalf of the company's long-term shareholders. Click here for additional information: https://kaskelalaw.com/case/array-digital/ Since August 2025, shares of Array's common stock have declined in value from a trading price of over $70.00 per share to a current price of approximately $55.00 per share – a cumulative decline of over 21% in value.